Seizert Capital Partners’s PDL BioPharma, Inc. PDLI Stock Holding History

Seizert Capital Partners’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-161,998	Closed	-$476K	–	262
2018 Q2	$476K	Hold	161,998	–	–	0.02%	161
2018 Q1	$476K	Sell	161,998 -1,013,781	-86%	-$2.77M	0.02%	161
2017 Q4	$3.22M	Buy	1,175,779 +24,892	+2%	+$76.5K	0.12%	83
2017 Q3	$3.9M	Sell	1,150,887 -112,073	-9%	-$312K	0.14%	75
2017 Q2	$3.12M	Buy	1,262,960 +70,874	+6%	+$163K	0.11%	90
2017 Q1	$2.71M	Buy	+1,192,086	New	+$2.64M	0.1%	100
2015 Q3	–	Sell	-528,809	Closed	-$3.4M	–	215
2015 Q2	$3.4M	Sell	528,809 -28,235	-5%	-$189K	0.09%	123
2015 Q1	$3.92M	Sell	557,044 -36,570	-6%	-$265K	0.1%	119
2014 Q4	$4.58M	Sell	593,614 -83,419	-12%	-$660K	0.1%	112
2014 Q3	$5.06M	Buy	677,033 +60,878	+10%	+$565K	0.1%	105
2014 Q2	$5.96M	Buy	616,155 +398,335	+183%	+$3.55M	0.12%	88
2014 Q1	$1.81M	Buy	217,820 +51,370	+31%	+$440K	0.04%	95
2013 Q4	$1.41M	Buy	+166,450	New	+$1.4M	0.03%	108

Other funds holding PDLI

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Seizert Capital Partners's PDLI Position: Q3 2018 in Review

Seizert Capital Partners sold out of PDL BioPharma, Inc. (PDLI) in Q3 2018, closing a stake of 161,998 shares — an estimated $476K sold.

Seizert Capital Partners first reported a position in PDLI in Q4 2013 and held it in 13 quarters. The position peaked at $5.96M in Q2 2014. 152 funds tracked by Wall St. Rank hold PDLI as of Q3 2018.

Seizert Capital Partners reported no remaining PDL BioPharma, Inc. position as of Q3 2018 after selling out during the quarter.
Seizert Capital Partners sold 161,998 PDL BioPharma, Inc. shares in Q3 2018, an estimated $476K.
Seizert Capital Partners first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 13 quarters.
Seizert Capital Partners's PDL BioPharma, Inc. position peaked at $5.96M in Q2 2014.
152 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2018.

Based on Seizert Capital Partners's 13F filing for Q3 2018, filed 9 Nov 2018.